AIM
MRNA icon

Achmea Investment Management’s Moderna MRNA Stock Holding History

Achmea Investment Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-27,763
Closed -$2.76M – 463
2023
Q4 		$2.76M Sell
27,763
-1,175
-4% -$98.8K 0.06% 289
2023
Q3 		$2.99M Sell
28,938
-17,981
-38% -$2.01M 0.07% 273
2023
Q2 		$5.7M Buy
46,919
+11,919
+34% +$1.59M 0.12% 186
2023
Q1 		$5.38M Buy
35,000
+1,590
+5% +$262K 0.16% 159
2022
Q4 		$5.62M Sell
33,410
-6,570
-16% -$1.07M 0.19% 144
2022
Q3 		$4.73M Sell
39,980
-17,664
-31% -$2.68M 0.17% 148
2022
Q2 		$8.23M Sell
57,644
-28,073
-33% -$4.01M 0.27% 93
2022
Q1 		$14.8M Buy
+85,717
New +$14.4M 0.38% 55
2021
Q4 		– Sell
-49,235
Closed -$18.9M – 425
2021
Q3 		$18.9M Buy
49,235
+26,454
+116% +$9.76M 0.58% 30
2021
Q2 		$5.35M Buy
22,781
+5,656
+33% +$1.01M 0.18% 154
2021
Q1 		$2.24M Buy
17,125
+701
+4% +$102K 0.08% 301
2020
Q4 		$1.72M Buy
16,424
+7,380
+82% +$747K 0.06% 334
2020
Q3 		$640K Sell
9,044
-10,886
-55% -$759K 0.03% 421
2020
Q2 		$1.28M Buy
+19,930
New +$1.09M 0.04% 216

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Achmea Investment Management's MRNA Position: Q1 2024 in Review

Achmea Investment Management sold out of Moderna (MRNA) in Q1 2024, closing a stake of 27,763 shares — an estimated $2.76M sold.

Achmea Investment Management first reported a position in MRNA in Q2 2020 and held it in 14 quarters. The position peaked at $18.9M in Q3 2021. 902 funds tracked by Wall St. Rank hold MRNA as of Q1 2024.

  • Achmea Investment Management reported no remaining Moderna position as of Q1 2024 after selling out during the quarter.
  • Achmea Investment Management sold 27,763 Moderna shares in Q1 2024, an estimated $2.76M.
  • Achmea Investment Management first reported a position in Moderna in Q2 2020 and held it in 14 quarters.
  • Achmea Investment Management's Moderna position peaked at $18.9M in Q3 2021.
  • 902 funds tracked by Wall St. Rank held Moderna as of Q1 2024.

Based on Achmea Investment Management's 13F filing for Q1 2024, filed 8 May 2024.